Multipl Sklerozda Hastalık Modifiye Edici Tedaviler: Oral Tedaviler

Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos. 2003 Sep 6;24(6):259–73.

Biogen Idec. Tecfidera (dimethyl fumarate): US prescribing information. Available at http://www. tecfidera.com/pdfs/full-prescribing-information.pdf. 2024.

Burness CB, Deeks ED. Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis. CNS Drugs. 2014 Apr 13;28(4):373–87.

Bomprezzi R. Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview. Ther Adv Neurol Disord. 2015 Jan 6;8(1):20–30.

de Jong R, Bezemer AC, Zomerdijk TPL, van de Pouw‐Kraan T, Ottenhoff THM, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti‐psoriasis agent monomethylfumarate. Eur J Immunol. 1996 Sep 17;26(9):2067–74.

Ozel O, Vaughn CB, Eckert SP, Jakimovski D, Lizarraga AA, Weinstock-Guttman B.

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives

. Patient Relat Outcome Meas. 2019 Dec;Volume 10:373–84.

Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. Journal of Clinical Investigation. 2014 May 1;124(5):2188–92.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine. 2012 Sep 20;367(12):1087–97.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2012 Sep 20;367(12):1098–107.

Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS). Multiple Sclerosis Journal. 2015 Jan 2;21(1):57–66.

Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS). Pediatr Neurol. 2018 Jun;83:19–24.

Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M, Blaschek A, Valis M, Aaen G, et al. Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis. Front Neurol. 2021 Jan 4;11.

Vermersch P, Scaramozza M, Levin S, Alroughani R, Deiva K, Pozzilli C, et al. Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Netw Open. 2022 Sep 28;5(9):e2230439.

Kornbluh AB, Kahn I. Pediatric Multiple Sclerosis. Semin Pediatr Neurol. 2023 Jul;46:101054.

Phillips JT, Agrella S, Fox RJ. Dimethyl Fumarate. Int J MS Care. 2017 Mar 1;19(2):74–83.

Macaron G, Feng J, Moodley M, Rensel M. Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. Curr Treat Options Neurol. 2019 Oct 27;21(10):50.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine. 2018 Sep 13;379(11):1017–27.

https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya. 2019.

Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Multiple Sclerosis Journal. 2014 Apr 15;20(4):471–80.

Trepel F. Number and distribution of lymphocytes in man. A critical analysis. Klin Wochenschr. 1974 Jun;52(11):511–5.

Cross A, Riley C. Treatment of Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology. 2022 Aug;28(4):1025–51.

Miron VE, Hall JA, Kennedy TE, Soliven B, Antel JP. Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod. Am J Pathol. 2008 Oct;173(4):1143–52.

Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New England Journal of Medicine. 2010 Feb 4;362(5):387–401.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2010 Feb 4;362(5):402–15.

Kappos L, O’Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, et al. Long-term effects of fingolimod in multiple sclerosis. Neurology. 2015 Apr 14;84(15):1582–91.

Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011 Jun;10(6):520–9.

Teriflunamide Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio. 2024;

Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and Its Mechanism of Action in Multiple Sclerosis. Drugs. 2014 Apr 17;74(6):659–74.

O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2011 Oct 6;365(14):1293–303.

Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar;13(3):247–56.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal. 2014 May 14;20(6):705–16.

Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, et al. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021 Dec;20(12):1001–11.

Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, et al. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS. Multiple Sclerosis Journal. 2024 Jun 15;30(7):833–42.

Mavenclad EU SmPC. Available at: medicines.org.uk/emc/medicine/34044. 2024;

Suntornlohanakul R, Yeh EA. Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered? Pediatric Drugs. 2024 Dec 26;

CLADRIBINE PRODUCT INFORMATION. https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad. 2024.

Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. Clin Pharmacokinet. 2019 Mar 10;58(3):283–97.

Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5’-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993 Feb 1;81(3):597–601.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2010 Feb 4;362(5):416–26.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal. 2018 Oct 5;24(12):1594–604.

Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, et al. Cladribine tablets added to IFN-β in active relapsing MS. Neurol Neuroimmunol Neuroinflamm. 2018 Sep;5(5).

Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, et al. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Lancet Child Adolesc Health. 2024 May;8(5):348–57.